Upadacitinib

Upadacitinib is an approved oral JAK1 inhibitor with evidence for inducing and maintaining remission in moderate-to-severe Crohn's disease, including colonic-predominant disease. Patients and clinicians may consider it...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from moomoo.com.

Some infections (here, HIV) can closely mimic very early onset IBD. Recognizing progressive lymphopenia or unusual infections can change diagnosis and treatment, which matters because immunosuppression can worsen...

Longer-term and real-world data help patients and clinicians understand how well risankizumab and upadacitinib maintain clinical and endoscopic improvement over years of treatment, and early data on an investigational...

A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...

Real-world data on upadacitinib help patients and clinicians understand how the drug performs outside clinical trials, including how long patients stay on treatment, remission rates, and common side effects.

Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...

Intestinal fibrosis can cause strictures and obstructive complications that often lead to surgery. Research identifying the cellular drivers and druggable pathways could guide development of treatments to prevent or slow...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

The analysis helps compare multiple advanced therapies when head‑to‑head trials are lacking, which may inform drug selection for induction and maintenance in moderate‑to‑severe UC, including for patients who have failed...

Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...

Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Inflammatory bowel disease, Upadacitinib, and Tofacitinib.

Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...

New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.

New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...

The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...

Cure8 could only read part of this source from Intestinal Research, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease.

The review compiles trial and real-world safety data for upadacitinib in IBD and highlights monitoring needs and infection risks (notably herpes zoster), which are directly relevant when choosing or managing JAK...

Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. The original article is from Clinical Gastroenterology and...

This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...

Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.

This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.

Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Alimentary Pharmacology &...

This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.

Patients and clinicians often face trade-offs when managing overlapping immune-mediated diseases. This report shows how past thromboembolic events and disease remission status can steer therapy away from JAK inhibitors...

Perianal fistulising Crohn's disease is hard to treat and often fails anti-TNF drugs. This study will provide real-world data on whether upadacitinib can be effective and safe for patients with refractory perianal...

Real-world registry data on upadacitinib can help patients and clinicians understand how the drug performs outside clinical trials, including patterns of use, effectiveness, and safety over time.

This study compares two JAK inhibitors (upadacitinib and tofacitinib) used as rescue therapy for acute severe ulcerative colitis and reports lower 1‑year colectomy rates with upadacitinib. That could influence choices...

Regulatory approvals and trial activity for upadacitinib (Rinvoq) affect availability and prescribing patterns for immunomodulatory treatment options used across autoimmune and inflammatory diseases, including IBD.

This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...

Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...

The review directly compares randomized-trial evidence for JAK inhibitors in moderate-to-severe Crohn's disease and highlights which regimens (notably upadacitinib) showed the most consistent efficacy signals,...

This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...

The paper presents a validated lab method to detect and quantify enantiomeric impurities in upadacitinib, which supports drug quality and safety for patients treated with JAK‑1 inhibitors for IBD and other conditions.

Patients with moderate-to-severe Crohn's disease who do not respond to anti-TNF drugs have limited options. This study suggests combining ustekinumab with upadacitinib may improve endoscopic healing versus either drug...

This study models comparative cost-effectiveness across many advanced therapy sequences for moderate–severe ulcerative colitis in Japan; its findings could influence how health systems and clinicians consider first- and...

Older adults with IBD are under-represented in trials, so age-specific benefits and harms of newer oral drugs (JAK inhibitors and S1P modulators) are uncertain. Clinicians and patients may need to weigh efficacy against...

Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.

Switching biologics is a frequent and consequential decision in children with IBD; using TDM and a mechanism‑based approach can help choose whether to optimize, switch within class, or change drug class.

If you or your clinician are using upadacitinib for Crohn’s, intestinal ultrasound early in treatment may help predict who will not respond and who is more likely to relapse on maintenance dosing, potentially guiding...

This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while...

A JAK inhibitor (upadacitinib) used for moderate–severe ulcerative colitis can cause neutropenia; this case report discusses how it was identified and managed, which matters for patients on the drug and clinicians...

Cure8 found this source from Journal of paediatrics and child health, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. Open the original...

An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.

People with IBD or Crohn's disease considering or taking upadacitinib may worry about rare but serious risks such as heart attacks, strokes, or blood clots. This meta-analysis found no clear increase in those events...